comprehensive -WSS

comprehensive

author：knowledge 2025-09-06 02:10:31 - browse：1

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

hotspot

Wikipedia

WSS

The new shift in health care is toward less care

Study: AI not yet building 'n

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

What nurses really want: sufficient staffing for patient care

The Sacklers, horror, and ‘The Fall of the House of Usher’

FDA approves Recor Medical high blood pressure device

knowledge

comprehensive

hotspot

Medicare details structure of new drug price negotiation program

Bird flu outbreak in cows is latest avian flu curveball

In Memoriam: Notable people who died in 2023

Extreme heat events are a public health emergency

New air purifier tech could be key to improving indoor air quality

Sanofi strikes deal with Novavax, boosting the vaccine maker

Apple is now the first public company to be valued at $3 trillion

Making AI in medicine accessible to smaller, and rural hospitals

Novavax promises a turnaround & Lilly roils the obesity market

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Wikipedia

Readout LOUD podcast: What to know about H5N1 bird flu

Study: New antibiotic targets gonorrhea as well as last existing drug

White House calls on federal agencies to crack down on AI abuses

Steward Health Care files for bankruptcy

H5N1 bird flu: what we're starting to learn about infection in cows

Making AI in medicine accessible to smaller, and rural hospitals

hotspot

hotspot

Wikipedia

explore